Whether genetic risk features such as IKZF1 deletions, which are associated with unfavorable outcomes in BCR::ABL1-positive ALL, also play a role in CML-BP and should be considered in therapy stratification has not been investigated [28]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.